Project supported by the National Natural Science Foundation of China, No. 39390850.
Published online Apr 15, 1998. doi: 10.3748/wjg.v4.i2.171
Revised: January 4, 1998
Accepted: January 25, 1998
Published online: April 15, 1998
AIM: To observe the therapeutic effects of Sishengtang decoction in alleviating the toxic and side effects of transarterial embolization (TAE).
METHODS: Fifty-four patients with liver cancer were divided randomly into Sishengtang decoction group (34 cases) and control group (20 cases). The changes of clinical symptoms and peripheral hemogram and some cellular immune functions were observed before and two weeks after TAE.
RESULTS: Sishengtang decoction was superior to the control group in improving the digestive tract reaction. The leucocytes of peripheral blood and cellular immune functions (activities of NK cells and LAK cells) of control group decreased obviously after TAE, while that of Sishengtang decoction group decreased slightly, without obvious difference as compared with that of preoperation.
CONCLUSIONS: Sishengtang decoction might improve the clinical symptoms and increase the leucocytes of peripheral blood and the cellular immune functions of TAE patients.
- Citation: Chen Z, Ling CQ, Huang XQ, Zhang HW. Sishengtang decoction in alleviation of toxic and side effects of transarterial embolization. World J Gastroenterol 1998; 4(2): 171-173
- URL: https://www.wjgnet.com/1007-9327/full/v4/i2/171.htm
- DOI: https://dx.doi.org/10.3748/wjg.v4.i2.171
After clinical and experimental studies of antiradioactive reaction produced by Sishengtang decoction, we studied systematically the therapeutic effects of this decoction in alleviating the toxic and side effects of chemotherapy, and observe the changes of peripheral hemogram and the cellular immune functions.
Of 54 patients with liver cancer, submitted for TAE from May 1995 to October 1996, 48 were males and 6 females, aged from 31 to 74 years, averaging 48.8 years. Twenty-one cases were in stage III and 33 were in stage III clinically. These patients were divided into Sishengtang decoction group (34 cases) and control group (20 cases). There were 29 males and 5 females in the Sishengtang decoction group, with an average of 49.2 years of age, and 14 cases in stage II and 20 in stage III. In the control group, there were 19 males and 1 female, averaging 48.1 years in age, 7 in stage II and 13 in stage III.
Sishengtang decoction contains mainly: Radix As-tragli sen Hedysari 30 g, Radix Rehmanniae 10 g, Rhizoma Atractylodis Macrocephalac 9 g and Somen Colcis 15 g. Components were regulated according to symptoms (RCAS): Radix Asparagi 15 g and Radix Dphipogonis 15 g were added for mouth dryness; Radix Codonopsis Pilosnlae 30 g and Poria 15 g were added for lassitude; Rhizoma Dioscoreae 9 g, Endothelinm Cornenm Gigeriaw Galli 12 g, Fructus Crataegi 12 g, Fructus Hordei Germinatus 12 g and Massa Fermentata Medicinalis 12 g were added for anorexia.
Sishengtang decoction and RCAS were used concomitantly in the Sishengtang decoction group. They were given a week before TAE, at 1 dose daily divided in the morning and evening. Only RCAS was used in the control group, administration and dosage were the same as the Sishengtang decoction group.
The changes in clinical symptoms of all the 54 patients were recorded one day and 5 d respectively after TAE and the peripheral hemogram and some cellular immune functions were measured 1 week before and 2 weeks after TAE. The activities of NK and LAK cells were detected by radioimmunoassay, with K502 and Raji, as target cells. Detailed processes were in accordance with Reference 2 and 3.
The data were expressed as x-± s, and the comparison between the two groups was made by χ2 test and t test.
In 3 main clinical symptoms observed, the effect of Sishengtang decoction was superior to that of the control group (Table 1).
There was no obvious difference in peripheral hemogram and some cellular immune functions between Sishengtang decoction group and control group before therapy, but with no obvious decline of these two indexes in the control group after therapy (Table 2).
|Groups||n||WBC (× 109/L)||PLT (× 109/L)||NK activities (%)||LAK activities (%)|
|Before treatment||4.62 ± 0.62||123.00 ± 37.45||32.03 ± 7.25||34.07 ± 6.69|
|After treatment||4.44 ± 0.63||116.23 ± 29.42||31.04 ± 6.92||32.03 ± 6.76|
|Before treatment||5.31 ± 0.82||31.92 ± 47.93||141.20 ± 5.22||32.87 ± 4.85|
|After treatment||3.87 ± 0.38||126.80 ± 37.58||26.16 ± 7.77a||27.16 ± 5.74a|
TAE is one of the most effective therapies for the patients who can not be operated on and for some of the patients with recurrent liver cancer after operation. But the toxic and side effects of TAE, such as decreased leucocytes in peripheral blood, reaction of digestive tract and decline of body immune functions, not only result in great pain for patients, but also become a main factor that influences the therapeutic effects of TAE. So it has been an important topic to seek effective traditional Chinese medicine or complex prescriptions which can reduce the toxic and side effects of chemotherapy.
Sishengtang decoction is a basic prescription, made according to the theory of traditional Chinese medicine and clinical experience from the specialists to relieve the patients from the toxic and side effects of radiotherapy and chemotherapy. In this prescription, Radix Astragali sen Hedysari invigorates the vital energy and the spleen; Radix Rehmanniae nourishes yin and invigorates the Kidney; Rhizoma Atractylodis Macrocephalae and Semen Coicis invigorate the spleen and regulate the middle warmer, and prevent the greasy of Radix Astragali sen Hedysari and Radix Rehmanniae. This prescription acts to invigorate both vital energy and yin, take care of Spleen and Kidney, not only prevent the exhaustion of congenital yin and yang, but also protect the acquired essential substance from food. Four elements of this prescription are all used unpreparedly in order to prevent too much dryness or greasiness of the herbal characters, which is of great significance in maintaining the process of digestion of the middle warmer and relieving the digestive tract reaction. According to the modern pharmacological analysis, Radix Astragli sen Hedysari and Rhizoma Atractylodis Macrocephalac can improve body immune function and increase leucocytes in peripheral blood; and Somen Colcis has the anticancer effects if used unprepared. When used together, these four elements will have the functions to reduce toxicin and promote their effects.
In the improvement of clinical symptoms and results of laboratory examinations, RCAS, used in the control group, though can partially improve the clinical symptoms, its effects are not as good as Sishengtang decoction. As for the increase of leucocytes in peripheral blood, the effects of Sishengtang decoction group is also superior to that of the control group. The results indicated that Sishengtang decoction can alleviate the toxic and side effects of chemotherapy.
In term of the cellular immune functions of TAE patients, the activities of NK and LAK cells of the control group were decreased markedly, but without significant difference in the Sishengtang group compared with that of preoperation. The results showed that Sishengtang decoction might increase the leucocytes in peripheral blood and cellular immune functions, which is important in promoting the recovery of patients and enhancing the effects of TAE itself. The mechanism may be related to its enhancement and protection of blood production by marrow.
|1.||Ling CQ, Chen LQ, Chen Z, Huang XQ. Clinical and experimental study of the resistance effects of Sishengtang decoction on toxic and side effects in radiotherapy and chemotherapy. J Tradit Chin Med. 1993;34:733.|
|2.||Chao XT. Basic and clinical study of Interleukin-2. Beijing: Beijing Science and Technology Publisher. 1990;48-53.|
|3.||Zhu ZY. Methodology of practical medical tests. Beijing: People's Military Medical Publisher. 1992;828-829.|
|4.||Ling CQ, Shi JH, sdsdsd Z, Zhang HW. The experimental study of Sishengtang decoction in promoting and protecting marrow blood making. China J Basic Med Tradit Chin Med. 1997;5:68.|